Summit Securities Group’s Novavax NVAX Stock Holding History

Summit Securities Group’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-337	Closed	-$4K	–	824
2024 Q3	$4K	Buy	+337	New	+$4.35K	﹤0.01%	435

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Summit Securities Group's NVAX Position: Q4 2024 in Review

Summit Securities Group sold out of Novavax (NVAX) in Q4 2024, closing a stake of 337 shares — an estimated $4K sold.

Summit Securities Group first reported a position in NVAX in Q3 2024 and held it in 1 quarter. The position peaked at $4K in Q3 2024. 234 funds tracked by Wall St. Rank hold NVAX as of Q4 2024.

Summit Securities Group reported no remaining Novavax position as of Q4 2024 after selling out during the quarter.
Summit Securities Group sold 337 Novavax shares in Q4 2024, an estimated $4K.
Summit Securities Group first reported a position in Novavax in Q3 2024 and held it in 1 quarter.
Summit Securities Group's Novavax position peaked at $4K in Q3 2024.
234 funds tracked by Wall St. Rank held Novavax as of Q4 2024.

Based on Summit Securities Group's 13F filing for Q4 2024, filed 12 Feb 2025.